Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Trial Profile

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Ingenol mebutate (Primary) ; Diclofenac
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 14 Oct 2017 Primary endpoint (Complete clearance of all AKs) has been met as per the results published in the British Journal of Dermatology
    • 14 Oct 2017 Results published in the British Journal of Dermatology
    • 16 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top